Falci Cristina, Dieci Maria Vittoria, Guarneri Valentina, Soldà Caterina, Bria Emilio, Tortora Giampaolo, Conte Pierfranco
Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, via Gattamelata 64, 35128, Padova, Italy.
Expert Rev Anticancer Ther. 2014 Sep;14(9):1041-50. doi: 10.1586/14737140.2014.922415. Epub 2014 Jun 23.
Over the past years, although no increase in the cure rate for advanced epithelial ovarian cancer patients has been achieved, a slow prolongation in patients survival has been observed, thanks to the introduction of effective second line or salvage therapies. Attempts to disease chronicization seem therefore of value in this setting. A major effort has been pursued to establish the role of maintenance therapies for epithelial ovarian cancer patients. Although chemotherapy does not seem to have an effective role, promising results are coming from trials investigating maintenance targeted treatments, especially with antiangiogenic agents or PARP inhibitors for selected patients. The aim of this article is to review current evidences on maintenance therapy for epithelial ovarian cancer and put the results in perspective.
在过去几年中，尽管晚期上皮性卵巢癌患者的治愈率没有提高，但由于引入了有效的二线或挽救性治疗方法，患者的生存期出现了缓慢延长。因此，使疾病慢性化的尝试在这种情况下似乎具有价值。人们已经做出了巨大努力来确立维持治疗在上皮性卵巢癌患者中的作用。尽管化疗似乎没有起到有效的作用，但针对维持性靶向治疗的试验正取得令人鼓舞的结果，特别是针对特定患者使用抗血管生成药物或PARP抑制剂。本文的目的是综述目前关于上皮性卵巢癌维持治疗的证据，并对结果进行展望。
